19 completed, 7 terminated, 4 withdrawn, 2 unknown. 32 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Completed 19, Terminated 7, Withdrawn 4, Unknown 2 |
| Phase 1 | 5 | Completed 3, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow BKM120: new trials by email Literature Review of BKM120 trials Research Report on BKM120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer BKM120 - Treatment for Metastatic or Locally Advanced Cervical Cancer | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2015-11-01 | 2017-04-20 | |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer | Phase 2 | Terminated | Anne Chang | 10 | 2015-02-01 | 2019-01-29 |
| Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer BKM120, Tamoxifen - Breast Cancer | Phase 2 | Completed | University Hospital, Essen | 48 | 2014-12-01 | 2018-04-20 |
| A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas BKM120 - Thymoma | Phase 2 | Completed | Patrick Joseph Loehrer Sr. | 14 | 2014-10-01 | 2022-04-11 |
| Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer paclitaxel, BKM120 - Breast Neoplasms | Phase 2 | Withdrawn | Washington University School of Medicine | 2014-08-01 | 2014-12-08 | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma LGX818, MEK162, LEE011 - Melanoma | Phase 2 | Completed | Pfizer | 158 | 2014-07-23 | 2024-03-05 |
| STAR Cape+BKM120 MBC With Brain Met BKM120, capecitabine, Trastuzumab - Brain Metastases, Breast Cancer | Phase 2 | Completed | US Oncology Research | 10 | 2014-05-29 | 2022-02-07 |
| BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers BKM120 - Endometrial Cancer | Phase 2 | Withdrawn | University of Utah | 2014-05-01 | 2014-07-29 | |
| Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women alpelisib, buparlisib, Placebo - Breast Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 340 | 2014-03-11 | 2018-09-14 |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 43 | 2014-01-09 | 2018-05-30 |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Buparlisib, Buparlisib matching Placebo, Paclitaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 157 | 2013-10-01 | 2018-07-24 |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer BKM120, Trastuzumab, Paclitaxel - HER2-positive Newly Diagnosed, Primary Breast Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 50 | 2013-09-03 | 2019-11-14 |
| BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy BKM120 - Esophageal Cancer | Phase 2 | Terminated | Prince of Songkla University | 5 | 2013-07-01 | 2021-10-11 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Neoadjuvant BKM120 in High-risk Prostate Cancer BKM120 - High Risk Prostate Cancer | Phase 2 | Terminated | Won Kim | 11 | 2013-04-23 | 2021-01-13 |
| A Multicenter Phase II Pilot Open Label BKM120 - Thyroid Cancers | Phase 2 | Unknown | Hospices Civils de Lyon | 47 | 2013-04-01 | 2016-10-05 |
| BKM120 for Patients With PI3K-activated Tumors BKM120 - PI3K Pathway Activated Tumors | Phase 2 | Completed | Novartis Pharmaceuticals | 146 | 2013-03-29 | 2018-10-19 |
| Safety and Efficacy of BKM120 in Relapsed and Refractory NHL Buparlisib - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | Phase 2 | Completed | Novartis Pharmaceuticals | 72 | 2013-02-28 | 2018-09-28 |
| Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive BKM120 - Head and Neck Neoplasms, Neoplasm Metastasis | Phase 2 | Completed | Centre Leon Berard | 58 | 2013-01-01 | 2019-06-24 |
| P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. BKM120, Panitumumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Canadian Cancer Trials Group | 22 | 2012-09-06 | 2023-08-04 |
Showing 20 of 32. Sign in to see all of them.
Breast Neoplasms (10) · Neoplasm Metastasis (7) · Brain Neoplasms (4) · Glioblastoma (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Head and Neck Neoplasms (2) · Prostatic Neoplasms (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Basal Cell Nevus Syndrome (1) · Carcinoma, Basal Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1)
Novartis Pharmaceuticals (11) · ARCAGY/ GINECO GROUP (1) · Andrew J. Armstrong, MD (1) · Anne Chang (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Dana-Farber Cancer Institute (1) · Hospices Civils de Lyon (1) · L. Nicolas Gonzalez Castro, MD, PhD (1) · Massachusetts General Hospital (1) · Patrick Joseph Loehrer Sr. (1) · Pfizer (1) · Prince of Songkla University (1) · SCRI Development Innovations, LLC (1) · SOLTI Breast Cancer Research Group (1)
United States (21) · Spain (11) · Germany (10) · France (9) · Italy (8) · Canada (7) · Australia (6) · Belgium (6) · Brazil (5) · Japan (5) · Netherlands (5) · United Kingdom (5) · South Korea (4) · Austria (3) · Hong Kong (3)
Andrew Armstrong, MD, ScM (1) · Anja Welt, MD (1) · Anne Lynn Chang, MD (1) · Arunee Dechaphunkul, MD (1) · Byoung Chul Cho, M.D., Ph.D. (1) · Derek Jonker (1) · Eric Winer, MD (1) · Foluso Ademuyiwa, M.D., M.P.H. (1) · Isabelle Ray-Coquard, MD (1) · Jeffrey A Engelman, MD, PhD (1) · Jordi Rodon, MD (1) · Jose Baselga, MD (1) · Joyce A. O'Shaughnessy, MD (1)
PMID 33138866, PMID 26098748, PMID 26766736, PMID 28131786, PMID 28923573, PMID 28971900, PMID 29175429, PMID 30105951, PMID 30715997, PMID 30723140, PMID 31506897, PMID 31776899, PMID 32963347, PMID 34376578, PMID 36330484, PMID 39808408, PMID 41914670
2009 (1), 2014 (1)